Barclays PLC Immunome Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Immunome Inc. stock. As of the latest transaction made, Barclays PLC holds 104,314 shares of IMNM stock, worth $993,069. This represents 0.0% of its overall portfolio holdings.
Number of Shares
104,314
Previous 105,886
1.48%
Holding current value
$993,069
Previous $1.55 Million
28.44%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding IMNM
# of Institutions
124Shares Held
45.4MCall Options Held
38.7KPut Options Held
2.05M-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.5MShares$52.4 Million0.04% of portfolio
-
Redmile Group, LLC San Francisco, CA4.83MShares$46 Million3.87% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$36.9 Million1.86% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$35.8 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.46MShares$32.9 Million0.02% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $115M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...